JPWO2022080481A1 - - Google Patents

Info

Publication number
JPWO2022080481A1
JPWO2022080481A1 JP2022557474A JP2022557474A JPWO2022080481A1 JP WO2022080481 A1 JPWO2022080481 A1 JP WO2022080481A1 JP 2022557474 A JP2022557474 A JP 2022557474A JP 2022557474 A JP2022557474 A JP 2022557474A JP WO2022080481 A1 JPWO2022080481 A1 JP WO2022080481A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557474A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022080481A1 publication Critical patent/JPWO2022080481A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022557474A 2020-10-16 2021-10-15 Pending JPWO2022080481A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020174840 2020-10-16
JP2020215740 2020-12-24
JP2021024688 2021-02-18
PCT/JP2021/038207 WO2022080481A1 (ja) 2020-10-16 2021-10-15 抗her2抗体の放射性複合体、及び、放射性医薬

Publications (1)

Publication Number Publication Date
JPWO2022080481A1 true JPWO2022080481A1 (cg-RX-API-DMAC7.html) 2022-04-21

Family

ID=81208085

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557474A Pending JPWO2022080481A1 (cg-RX-API-DMAC7.html) 2020-10-16 2021-10-15

Country Status (10)

Country Link
US (1) US20230390425A1 (cg-RX-API-DMAC7.html)
EP (1) EP4230637A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022080481A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230088764A (cg-RX-API-DMAC7.html)
AU (1) AU2021361746A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198721A1 (cg-RX-API-DMAC7.html)
IL (1) IL302111A (cg-RX-API-DMAC7.html)
MX (1) MX2023004428A (cg-RX-API-DMAC7.html)
TW (1) TW202233247A (cg-RX-API-DMAC7.html)
WO (1) WO2022080481A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017217347A1 (ja) * 2016-06-13 2017-12-21 国立大学法人鹿児島大学 IgG結合ペプチドによる部位特異的RI標識抗体
WO2019125982A1 (en) * 2017-12-18 2019-06-27 Janssen Biotech, Inc. Radiolabeling of polypeptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP6872181B2 (ja) 2015-05-20 2021-05-19 国立大学法人 鹿児島大学 IgG結合ペプチドによる抗体の特異的修飾
WO2018230257A1 (ja) 2017-06-16 2018-12-20 国立大学法人鹿児島大学 IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾
CA3097101A1 (en) * 2018-04-16 2019-10-24 Nihon Medi-Physics Co., Ltd. Modified antibody and radioactive metal-labelled antibody
JP2020021574A (ja) 2018-07-30 2020-02-06 パナソニックIpマネジメント株式会社 光源ユニット、照明器具、及び照明器具用の拡張構造
JP2020174840A (ja) 2019-04-17 2020-10-29 豊丸産業株式会社 遊技機
JP7272895B2 (ja) 2019-08-02 2023-05-12 清水建設株式会社 水平搬送台車
PH12022550894A1 (en) * 2019-10-18 2023-03-27 Nihon Mediphysics Co Ltd Ri-labeled humanized antibody
CN114555132A (zh) * 2019-10-18 2022-05-27 日本医事物理股份有限公司 放射性金属标记抗体的制造方法
JP7680745B2 (ja) 2019-10-24 2025-05-21 国立大学法人 鹿児島大学 1価ccap生成物の製造方法
JP7154465B1 (ja) * 2021-01-08 2022-10-17 日本メジフィジックス株式会社 Ac-225溶液の製造方法およびAc-225溶液を用いた医薬の製造方法
JPWO2023033022A1 (cg-RX-API-DMAC7.html) * 2021-08-31 2023-03-09

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017217347A1 (ja) * 2016-06-13 2017-12-21 国立大学法人鹿児島大学 IgG結合ペプチドによる部位特異的RI標識抗体
WO2019125982A1 (en) * 2017-12-18 2019-06-27 Janssen Biotech, Inc. Radiolabeling of polypeptides

Also Published As

Publication number Publication date
IL302111A (en) 2023-06-01
CA3198721A1 (en) 2022-04-21
MX2023004428A (es) 2023-05-04
TW202233247A (zh) 2022-09-01
US20230390425A1 (en) 2023-12-07
EP4230637A1 (en) 2023-08-23
KR20230088764A (ko) 2023-06-20
AU2021361746A1 (en) 2023-06-22
WO2022080481A1 (ja) 2022-04-21
AU2021361746A9 (en) 2024-06-27
EP4230637A4 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
BR102021007058A2 (cg-RX-API-DMAC7.html)
BR102020022030A2 (cg-RX-API-DMAC7.html)
BR102021013306B1 (pt) Disposição introduzida em forno de pizza, com dispostivo de regulagem de altura da esteira com ajustes gradual escalonado
BR102021010942B1 (pt) Dispositivo mecânico para abertura e fechamento de portas para diferentes tipos de maçaneta, bola ou alavanca, acionado por pedal
BR102021010384B1 (pt) Equipamento para limpeza e/ou teste de bicos injetores com alta pressão
BR102021009961B1 (pt) Sistema e método para aproveitamento da água de injeção dessulfatada de plataformas marítimas para utilização em squeezes de inibição
BR102021007825B1 (pt) Equipamento de entretenimento e contemplação visual por cabines rotacionais e com giro radial e axial de 360 graus, para instalação em coberturas de edificações, penhascos ou encostas de elevações geográficas abissais
BR102021006565B1 (pt) Máquina de acabamento de estradas e método para operar a mesma
BR102021005700B1 (pt) Selo irregular para redução de ruído em aeronaves
BR102021005383B1 (pt) Método de perfurar um furo de poço marítimo com circulação reversa de fluido sem uso de tubulares de riser de perfuração
BR102021003589B1 (pt) Método para fabricar uma estrutura monolítica em formato de caixa para fuselagens e asas de aeronave usando um material prepreg de matriz de polímero reforçada com fibra
BR102021000474B1 (pt) Aparelho de pino de medição, sistema de amortecimento multiator, e, conjunto de amortecedor de impacto
BR102020026775B1 (pt) Montagem de painel de malha de arame soldado e uma ou mais armações, e parede ou teto reforçado por uma ou mais montagens
BR102020026454B1 (pt) Membrana de nanocelulose bacteriana e seu uso como bolus em radioterapia
BR102020026302B1 (pt) Processo de produção de corante natural azul
BR102020023974B1 (pt) Revestimento de amarras para redução de arrasto longitudinal
BR102020021170B1 (pt) Composição, formulações orais e uso
BR102020018864B1 (pt) Grade de ventilação modular
BR102020018483B1 (pt) Dispositivo mecânico para arraste de cabeçote móvel para realização de furos, alargamentos, roscas com machos por intermédio de automatização em tornos mecânicos horizontais
BR102020016764B1 (pt) Forma de dosagem intrauretral de medicamento; e dispositivo
BR102020013192B1 (pt) Distribuidor de fertilizante sólido para equipamentos agrícolas, e equipamento agrícola dotado de distribuidor de fertilizante sólido
BR102020010912B1 (pt) Aparelho compacto de eletrólise de baixo custo
BR102020007524B1 (pt) Sistema de montagem e controle de acumuladores em estações de trabalho
BR102020005641B1 (pt) Método integrado de cultura do peixe lambari-do-rabo-amarelo, camarão-da-amazônia e o peixe curimbatá
BR102020004560B1 (pt) Rotor eólico utilizando duplas-pás inteiriças para geração de potência

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260804